Vaxcyte, Inc. (PCVX)
NASDAQ: PCVX · Real-Time Price · USD
58.73
-0.99 (-1.66%)
At close: Apr 28, 2026, 4:00 PM EDT
58.17
-0.56 (-0.95%)
After-hours: Apr 28, 2026, 5:29 PM EDT
Vaxcyte Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Vaxcyte stock have an average target of 88.25, with a low estimate of 38 and a high estimate of 116. The average target predicts an increase of 50.26% from the current stock price of 58.73.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 26, 2026.
Analyst Ratings
The average analyst rating for Vaxcyte stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Maintains $85 → $89 | Strong Buy | Maintains | $85 → $89 | +51.54% | Feb 26, 2026 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $116 | Strong Buy | Reiterates | $116 | +97.51% | Feb 2, 2026 |
| Needham | Needham | Strong Buy Maintains $90 → $110 | Strong Buy | Maintains | $90 → $110 | +87.30% | Jan 7, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $85 | Strong Buy | Reiterates | $85 | +44.73% | Nov 10, 2025 |
| BTIG | BTIG | Strong Buy Maintains $160 → $85 | Strong Buy | Maintains | $160 → $85 | +44.73% | Oct 16, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-7.29
from -5.63
EPS Next Year
-6.78
from -7.29
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -6.20 | -5.43 | ||||||
| Avg | -7.29 | -6.78 | ||||||
| Low | -8.61 | -8.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.